Background: EB1 (MAPRE2, microtubule-associated protein, RP/EB family, member 2, EB2, RP1) may influence tumorigenesis of colorectal cancers and proliferative control of normal cells. EB1 belongs to the intermediate/early gene family, involved in the signal transduction cascade downstream of the T cell receptor (TRC). Colorectal cancer is caused by the pathologic transformation of normal colonic epithelium to an adenomatous polyp, which can become an invasive cancer. APC (adenomatous polyposis coli) is a tumor suppressor gene, the mutation of which is one of the earliest events in colorectal carcinogenesis. A majority of the mutations result in the loss of the carboxy terminus of APC. EB1 has been shown to bind to the carboxy terminal region of APC, which implicates EB1 in APC suppression of colonic cancer. EB1 overexpression may play a role in the development of human esophageal squamous cell carcinoma by affecting APC function and activating the β-catenin/TCF pathway.

Description: Rabbit polyclonal to EB2

Immunogen: KLH conjugated synthetic peptide derived from EB2

Specificity:  ·Reacts with Human, Mouse and Rat.

·Isotype: IgG

Application:  ·Western blotting: 1/100-500. Predicted Mol wt: 37 kDa;

·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;

·Immunocytochemistry/Immunofluorescence: 1/100;

·Immunoprecipitation: 1/50;

·ELISA: 1/500;

·Optimal working dilutions must be determined by the end user.